Infectious Disease Diagnostics: Market, Technologies and NHS Adoption

Infectious disease diagnostics is one of the few areas of laboratory medicine where the commercial opportunity and the clinical urgency point in the same direction. Resistance is rising, pathogens keep emerging, and the tests that identify an infection quickly are the ones that determine whether treatment is targeted or guessed.

That does not make it an easy market to sell into. This guide maps the field for commercial teams: what infectious disease diagnostics covers, the technology layers and who buys each, what the market data does and does not tell you, how the UK is structured, and the route a new infection test has to travel before an NHS laboratory can use it. That last section is the one worth reading twice, because it is where most market entry plans turn out to be optimistic.

What Infectious Disease Diagnostics Covers

The field covers any test used to determine whether an infection is present, what is causing it, and how it should be treated. In practice that splits into four clinical questions, and they are not equally valuable.

• Is There An Infection? Distinguishing infection from other causes of the same presentation. Often the hardest question and the one with the least satisfying answers.
• What Is Causing It? Identifying the specific organism. The bulk of routine diagnostic activity.
• Will This Drug Work? Susceptibility and resistance, covered in depth in our guide to antibiotic susceptibility testing.
• Is It Spreading? Typing, sequencing and surveillance to detect transmission and outbreaks. Bought by public health rather than by hospitals.

Commercial teams frequently build products that answer the second question and pitch them as though they answered the third. Laboratories notice.

The Technology Layers

Infectious disease diagnostics is not one technology market. It is several, layered on top of each other, each with different buyers, price points and replacement cycles.

The layers coexist rather than replace one another, which is the single most common misreading of this market. Molecular testing did not eliminate culture, because culture still delivers the full susceptibility profile. Sequencing did not eliminate molecular testing, because it is slower and sits in reference laboratories. A product strategy premised on displacing an entire layer usually underestimates why that layer still exists.

How Large Is The Market, And Why Estimates Disagree

Published estimates of the global infectious disease diagnostics market vary enormously, and treating any single figure as authoritative is a mistake. The variation is not sloppiness. It reflects genuine differences in what is being counted.

• Whether COVID-19 Testing Is Included. Estimates spanning 2020 to 2022 include a volume of testing that has since collapsed, which produces both inflated baselines and alarming decline rates depending on the window chosen.
• Instruments Versus Consumables. Some models count placements, others count the recurring assay and reagent revenue that follows, which is where most of the value actually sits.
• Where The Boundary Sits. Whether sequencing, host response biomarkers, laboratory informatics and point of care testing are counted inside or outside the category.

The practical advice for a commercial or investment audience is to read the scope note before the headline number, and to build your own bottom up estimate for the specific segment and geography you are entering. A figure for the global market tells you very little about the addressable opportunity for a syndromic panel in English NHS microbiology.

The UK Picture

The UK is a disproportionately watched market because the NHS is a single large buyer with published data, which makes it useful as a reference case even for companies whose main revenue is elsewhere.

The scale is substantial. The 105 hospitals in England providing pathology services carry out around 1.12 billion tests a year across all disciplines. Those services have been consolidated into pathology networks, originally proposed as 29 with subsequent mergers leaving 27, each covering between three and eight hospital trusts on a hub and spoke model. Our guide to how NHS laboratory medicine is organised covers what that structure means for suppliers.

Two further features shape infection diagnostics specifically. Reference and specialist testing is centralised in UK Health Security Agency services, several of which are built on sequencing, as with the national mycobacterial service described in our guide to tuberculosis diagnostics. And the industry itself is represented by BIVDA, the not for profit trade association for the UK in vitro diagnostics sector, which is the body that engages with government on regulation and procurement.

How A New Infection Test Gets Adopted In The NHS

This is the section that matters commercially, and it is where optimistic plans meet reality. Adoption is not one decision. It is a sequence, and a product can fail at any stage while succeeding at all the others.

• Regulatory Approval. The device must be lawfully placed on the market. In Great Britain that means the UK Medical Devices Regulations 2002 and the UKCA mark, with CE marked devices currently still recognised. Our guide to IVDR and the UK regime covers this in detail.
• Health Technology Assessment. NICE evaluates diagnostics for clinical and cost effectiveness. Since 2022 it has also run an Early Value Assessment route for promising technologies where the evidence base is still emerging, and it is consolidating its previously separate diagnostics, medical technologies and interventional procedures programmes into a single HealthTech programme with a more rules based and predictable pathway to evaluation and funding.
• Funding. A positive assessment does not create a budget. Someone has to fund it, whether nationally, at network level, or by displacing existing spend.
• Network Procurement. Since consolidation, platform decisions are typically taken at pathology network level rather than by individual trusts, involving the network board, clinical leads, pathology IT and procurement.
• Local Verification. UKAS accreditation to ISO 15189 requires the laboratory to verify the method locally against its existing one before clinical use. This falls on laboratory staff and is a genuine barrier.
• Clinical And Stewardship Buy-In. For infection tests specifically, the antimicrobial stewardship team has effective veto, because a test that drives unnecessary antibiotic use will not be supported regardless of its performance.

Where The Commercial Opportunities Are

Reading the layers and the adoption route together points at where a new entrant realistically wins.

The recurring pattern is that the open opportunities are operational rather than purely analytical. The layers that already exist do the detection well. What they do less well is deliver an answer to the right person at the right time with acceptable staff effort.

Where FutureDx Summit Fits

FutureDx Summit 2026 is a two day conference dedicated to infectious disease and molecular diagnostics, held on 27 and 28 October 2026 at the Copthorne Tara Hotel London Kensington. It convenes 150+ validated NHS and industry decision-makers and is officially supported by BIVDA.

The programme covers the field rather than one corner of it, which is why it works as an orientation point for companies entering this market. Day 1 addresses sepsis diagnostics, drug resistant tuberculosis and blood borne virus screening in community settings. Day 2 moves to AI in diagnostics and precision medicine. The 23 confirmed speakers span the buying groups described above: Richard Vipond and Jean Lutamyo Mbisa, Deputy Directors at the UK Health Security Agency, for reference and genomics; Professor Adriana Calderaro of the University Hospital of Parma for clinical microbiology and virology; Peter Gayo Munthali for antimicrobial stewardship; Shazeena Hussain and Williams Tabowei for point of care testing; and Angela Douglas MBE and Helen Dent, President and Chief Executive of BIVDA, for the industry and regulatory view.

Sponsorship is organised by commercial objective, with routes for diagnostics companies generally, for AMR and sepsis diagnostics specifically, and for reaching infectious disease consultants. Packages include a defined number of pre-scheduled 1:1 meetings confirmed in advance, and the agenda covers both days.

What a focused conference does for a company entering this market is compress the relationship building described in the adoption section. It does not shorten NICE evaluation, create funding or guarantee adoption.

Frequently Asked Questions

What To Take From This

Infectious disease diagnostics rewards companies that understand it as several overlapping markets rather than one. The technology layers each persist for a reason, the buyers differ by layer, and in the UK the purchasing authority sits at network level while reference testing sits with national services.

The route to adoption is long and sequential, which has an unglamorous but important implication: the relationships that determine whether your product is evaluated at all are usually built years before the purchase order. That is the part of market entry most companies start too late.